Yoshida BA, Sokoloff MM, Welch DR, Rinker-Schaeffer CW. Metastasis-suppressor genes: a review and perspective on an emerging field. J Natl Cancer Inst. 2000;92:1717–30.
Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst. 1988;80:200–4.
Yu L, Wang X, Zhang W, Khan E, Lin C, Guo C. The multiple regulation of metastasis suppressor NM23-H1 in cancer. Life Sci. 2021;268:118995.
Kuo KT, Chen CL, Chou TY, Yeh CT, Lee WH, Wang LS. Nm23H1 mediates tumor invasion in esophageal squamous cell carcinoma by regulation of CLDN1 through the AKT signaling. Oncogenesis 2016;5:e239.
Li MQ, Shao J, Meng YH, Mei J, Wang Y, Li H, et al. NME1 suppression promotes growth, adhesion and implantation of endometrial stromal cells via Akt and MAPK/Erk1/2 signal pathways in the endometriotic milieu. Hum Reprod. 2013;28:2822–31.
Marshall JC, Collins J, Marino N, Steeg P. The Nm23-H1 metastasis suppressor as a translational target. Eur J Cancer. 2010;46:1278–82.
Ouatas T, Halverson D, Steeg PS. Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor gene expression in metastatic human breast carcinoma cells: new uses for old compounds. Clin Cancer Res. 2003;9:3763–72.
Lim J, Jang G, Kang S, Lee G, Nga do TT, Phuong, et al. Cell-permeable NM23 blocks the maintenance and progression of established pulmonary metastasis. Cancer Res. 2011;71:7216–25.
Chen W, Xiong S, Li J, Li X, Liu Y, Zou C, et al. The ubiquitin E3 ligase SCF-FBXO24 recognizes deacetylated nucleoside diphosphate kinase A to enhance its degradation. Mol Cell Biol. 2015;35:1001–13.
Fiore LS, Ganguly SS, Sledziona J, Cibull ML, Wang C, Richards DL, et al. c-Abl and Arg induce cathepsin-mediated lysosomal degradation of the NM23-H1 metastasis suppressor in invasive cancer. Oncogene. 2014;33:4508–20.
Khera L, Paul C, Kaul R. Hepatitis C Virus E1 protein promotes cell migration and invasion by modulating cellular metastasis suppressor Nm23-H1. Virology. 2017;506:110–20.
Paul C, Khera L, Kaul R. Hepatitis C virus core protein interacts with cellular metastasis suppressor Nm23-H1 and promotes cell migration and invasion. Arch Virol. 2019;164:1271–85.
Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011;13:215.
Dai X, Cheng H, Bai Z, Li J. Breast cancer cell line classification and its relevance with breast tumor subtyping. J Cancer. 2017;8:3131–41.
Singh B, Tai K, Madan S, Raythatha MR, Cady AM, Braunlin M, et al. Selection of metastatic breast cancer cells based on adaptability of their metabolic state. PLoS ONE. 2012;7:e36510.
Hartsough MT, Clare SE, Mair M, Elkahloun AG, Sgroi D, Osborne CK, et al. Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition. Cancer Res. 2001;61:2320–7.
Yu BYK, Tossounian MA, Hristov SD, Lawrence R, Arora P, Tsuchiya Y, et al. Regulation of metastasis suppressor NME1 by a key metabolic cofactor coenzyme A. Redox Biol. 2021;44:101978.
Schopf FH, Biebl MM, Buchner J. The HSP90 chaperone machinery. Nat Rev Mol Cell Biol. 2017;18:345–60.
Ciechanover A, Schwartz AL. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci USA. 1998;95:2727–30.
Salerno M, Palmieri D, Bouadis A, Halverson D, Steeg PS. Nm23-H1 metastasis suppressor expression level influences the binding properties, stability, and function of the kinase suppressor of Ras1 (KSR1) Erk scaffold in breast carcinoma cells. Mol Cell Biol. 2005;25:1379–88.
Hua K, Feng W, Cao Q, Zhou X, Lu X, Feng Y. Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer. Int J Oncol. 2008;33:959–67.
Zhang X, Fu LJ, Liu XQ, Hu ZY, Jiang Y, Gao RF, et al. nm23 regulates decidualization through the PI3K-Akt-mTOR signaling pathways in mice and humans. Hum Reprod. 2016;31:2339–51.
Abu-Taha IH, Vettel C, Wieland T. Targeting altered Nme heterooligomerization in disease? Oncotarget. 2018;9:1492–3.
Chen Y, Qian C, Guo C, Ge F, Zhang X, Gao X, et al. A Cys/Ser mutation of NDPK-A stabilizes its oligomerization state and enhances its activity. J Biochem. 2010;148:149–55.
Kim YI, Park S, Jeoung DI, Lee H. Point mutations affecting the oligomeric structure of Nm23-H1 abrogates its inhibitory activity on colonization and invasion of prostate cancer cells. Biochem Biophys Res. Commun. 2003;307:281–9.
Postel EH. NM23-NDP kinase. Int J Biochem Cell Biol. 1998;30:1291–5.
Souza TA, Trindade DM, Tonoli CC, Santos CR, Ward RJ, Arni RK, et al. Molecular adaptability of nucleoside diphosphate kinase b from trypanosomatid parasites: stability, oligomerization and structural determinants of nucleotide binding. Mol Biosyst. 2011;7:2189–95.
Webb PA, Perisic O, Mendola CE, Backer JM, Williams RL. The crystal structure of a human nucleoside diphosphate kinase, NM23-H2. J Mol Biol. 1995;251:574–87.
Li YJ, Liu W, Saini V, Wong YH. Mutations at the dimer interface and surface residues of Nm23-H1 metastasis suppressor affect its expression and function. Mol Cell Biochem. 2020;474:95–112.
Wayne N, Mishra P, Bolon DN. Hsp90 and client protein maturation. Methods Mol Biol. 2011;787:33–44.
Echeverria PC, Bernthaler A, Dupuis P, Mayer B, Picard D. An interaction network predicted from public data as a discovery tool: application to the Hsp90 molecular chaperone machine. PLoS ONE. 2011;6:e26044.
Li ZN, Luo Y. HSP90 inhibitors and cancer: prospects for use in targeted therapies (Review). Oncol Rep. 2023;49:6.
Hahn JS. The Hsp90 chaperone machinery: from structure to drug development. BMB Rep. 2009;42:623–30.
Giese A, Loo MA, Tran N, Haskett D, Coons SW, Berens ME. Dichotomy of astrocytoma migration and proliferation. Int J Cancer. 1996;67:275–82.
Hatzikirou H, Basanta D, Simon M, Schaller K, Deutsch A. ‘Go or grow’: the key to the emergence of invasion in tumour progression? Math Med Biol. 2012;29:49–65.
Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015;527:472–6.
Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527:525–30.
Otvos L Jr, Wade JD. Current challenges in peptide-based drug discovery. Front Chem. 2014;2:62.